Results 261 to 270 of about 1,471,327 (421)

Age and remission induction therapy for acute myeloid leukemia: An analysis of data from the Korean acute myeloid leukemia registry. [PDF]

PLoS One, 2021
Yoo KH, Kim HJ, Min YH, Hong DS, Lee WS, Kim HJ, Shin HJ, Park Y, Lee JH, Kim H.   +9 more
europepmc   +1 more source

TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes [PDF]

, 2016
et al,, Fronick, C. C., Fulton, R. S., Ley, T. J., Miller, C. A., O\u27Laughlin, M., Petti, A. A., Wartman, L. D., Wilson, R. K.   +8 more
core   +2 more sources

A Case of Daratumumab-Induced Significant Decrease in Donor-Specific HLA Antibodies and Remission Induction Before Haploidentical Stem Cell Transplantation in a Refractory B-ALL Patient. [PDF]

Cell Transplant, 2022
Li X, Zhu H, Sui T, Zhao X, Deng Q.
europepmc   +1 more source

Successful outcome of disseminated Candida tropicalis osteomyelitis on remission induction for childhood Philadelphia chromosome-positive acute lymphoblastic leukaemia-case report. [PDF]

Ital J Pediatr, 2021
Xie L, Long Q, Zhou G, Liu S, Wen FQ.
europepmc   +1 more source

TP53‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management

American Journal of Hematology, EarlyView.
ABSTRACT Alterations in the tumor suppressor gene TP53 are common in human cancers and are associated with an aggressive nature. Approximately 8%–12% of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) harbor TP53 mutations (TP53mut) and present immense challenges due to inherent chemoresistance and poor outcomes.
Mithun Vinod Shah, Daniel A. Arber, Devendra K. Hiwase   +2 more
wiley   +1 more source

Hyperacute reactivation of cytomegalovirus-induced gastroduodenitis during remission induction in a young male patient with granulomatosis with polyangiitis: a case report and review of literature. [PDF]

J Med Case Rep
George NA, Surendran S, Paulose RR, Pradeep M.   +3 more
europepmc   +1 more source

Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy

British Journal of Haematology, 2015
Seth E. Karol, E. Coustan-Smith, Xueyuan Cao, S. Shurtleff, S. Raimondi, J. Choi, Raul C. Ribeiro, G. Dahl, W. Bowman, J. Taub, B. Degar, W. Leung, J. Downing, C. Pui, J. Rubnitz, D. Campana, H. Inaba   +16 more
semanticscholar   +1 more source

Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives

American Journal of Hematology, EarlyView.
ABSTRACT Myelofibrosis (MF) is a myeloproliferative neoplasm that is accompanied by driver JAK2, CALR, or MPL mutations in more than 90% of cases, leading to constitutive activation of the JAK–STAT pathway. MF is a multifaceted disease characterized by trilineage myeloid proliferation with prominent megakaryocyte atypia and bone marrow fibrosis, as ...
Giuseppe G. Loscocco, Paola Guglielmelli
wiley   +1 more source

Remission induction therapies and long-term outcomes in granulomatosis with polyangiitis and microscopic polyangiitis: real-world data from a European cohort. [PDF]

Rheumatol Int
Krämer S, Vogt K, Schreibing TM, Busch M, Schmitt T, Bergner R, Mosberger S, Neumann T, Rauen T.   +8 more
europepmc   +1 more source

Treatment for Churg-Strauss Syndrome: Induction of Remission and Efficacy of Intravenous Immunoglobulin Therapy

, 2007
Masami Taniguchi, Naomi Tsurikisawa, Noritaka Higashi, Hiroshi Saito, Haruhisa Mita, Akio Mori, Hiroki Sakakibara, Kazuo Akiyama   +7 more
openalex   +1 more source